Spindler Strasse 11 • 37079 • Goettingen • Germany

Sartorius Stedim Biotech GmbH

Extended co-operation agreement to benefit Sartorius customers

By Sartorius Stedim Biotech GmbH ·

Agreement will enable customers to achieve easier scalability of processes ranging from lab-scale to commercial-scale production of biopharmaceuticals.

The Siemens technology group and Sartorius Stedim Biotech (SSB) have signed a long-term co-operation agreement. This agreement provides that SSB will preferably use Siemens automation technologies, including industrial PCs, the S7-1500 software controller, the TIA Portal and the SCADA system Simatic WinCC. These hardware and software components will be used in many products and solutions that SSB offers its customers for the development and manufacture of biopharmaceuticals, such as vaccines and monoclonal antibodies.

Extended co-operation agreement to benefit Sartorius customers

SSB has, for some time, already been using established Siemens automation solutions for process control in its large-scale bioreactor and filtration systems. To standardize its own product portfolio even further, SSB will introduce a new, configurable automation system for its range of systems. Under the agreement, co-operation between the two companies will, therefore, be extended to further SSB products. These will be successively equipped with Siemens automated solutions in the coming months and can thus be integrated into process control systems, such as Simatic PCS 7 and Simatic Batch. Essentially, such SSB products are single-use bioreactors of the BIOSTAT STR series, various filtration systems and the FlexAct system. The latter is a flexible module that is used to control many different process steps within biopharmaceutical production.

“By introducing this new automation platform and further standardizing our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions, such as SCADA, MES or ERP. At the same time, we are enabling them to achieve easier scalability of processes ranging from lab scale to commercial-scale production,” explained Dr Oscar-Werner Reif, Chief Technology Officer at SSB. “We have found an ideal partner in Siemens as one of the leading companies in automation,” continued Dr Reif.

Eckard Eberle, CEO of the Siemens Process Automation business unit, commented: “We are happy to support Sartorius Stedim Biotech with our unique and cohesive portfolio consisting of hardware, software and service throughout the entire system lifecycle. Based on our cooperation, users in the biopharmaceutical industry stand to benefit from higher efficiency, quality and flexibility, as well as faster time-to-market.”

During this year’s ACHEMA trade show that will be taking place from June 11 to June 15, 2018, in Frankfurt, Germany, Siemens and Sartorius Stedim Biotech will be jointly presenting the FlexAct module, a first product based on the new automation platform. Visitors and all others interested are cordially invited to obtain first-hand information at the Siemens AG booth in Hall 11/C3. A presentation on this product will be held in German on June 12 at 1:30 pm. and in English on June 13 at 1:00 p.m. and on 14 June at 2:00 pm.

Read More


Go to company page 

Categories

Market News
Biopharma News

Other news in “Market News”

Collaboration facilitates continuous manufacturing

Collaboration facilitates continuous manufacturing 

14 Jun 2018
Recipharm expands inhalation capabilities with acquisition of Sanofi CMO business located in UK

Recipharm expands inhalation capabilities with acquisition of Sanofi CMO business located in UK 

13 Jun 2018
Cambrex to expand generic API R&D capabilities at Milan, Italy site

Cambrex to expand generic API R&D capabilities at Milan, Italy site 

12 Jun 2018